Latest Health News
ICT&health World Conference 2026 Day One Highlights Global Health Insights
The first day of the ICT&health World Conference 2026 in Maastricht featured keynotes from leaders like Daniel Kraft and Larry Brilliant on healthcare transformation and smallpox eradication lessons. Discussions emphasized leadership, foresight, and scaling solutions for global health problems. The event launched a new podcast and continues through January 29.
BioNTech Gains FDA Fast Track for mRNA Cancer Immunotherapy BNT113
BioNTech received FDA Fast Track designation for BNT113 targeting HPV16-positive head and neck squamous cell carcinoma. The therapy encodes HPV16 E6 and E7 proteins to induce anti-tumor immune responses without chemotherapy. This addresses the seventh most common cancer worldwide with rising incidence.
MAIA Biotechnology Advances Aeganosine for Lung Cancer with FDA Fast Track
MAIA's telomere-targeting ateganosine secured FDA Fast Track for third-line non-small cell lung cancer after exceptional efficacy data. It shows superior disease control and survival versus standard care, targeting a $50+ billion market. The therapy positions for accelerated approval pathways.
Dr. Myron Cohen Steps Down from UNC Global Health Institute Leadership
Myron Cohen, MD, will end his tenure as Director of UNC's Institute for Global Health and Infectious Diseases by June 2026. Renowned for HIV prevention research, including the HPTN 052 trial named Science's 2011 Breakthrough of the Year. He also led COVID-19 prevention efforts via NIH networks.
Spanish Researchers Achieve Pancreatic Tumor Regression in Mice
A CNIO study in PNAS shows triple therapy targeting KRAS pathway eliminates pancreatic tumors in animal models without significant side effects. This combines a KRAS inhibitor, lung cancer drug, and protein degrader to overcome resistance. Spain sees over 10,300 cases yearly with <10% five-year survival.
FDA Lifts Hold on Intellia’s ATTRv-PN Gene Editing Trial
FDA lifted clinical hold on Intellia’s Nex-Z gene editing therapy trial for ATTRv-PN, a hereditary form of amyloidosis. This advances in vivo gene therapies amid 2026 expectations for CAR-T and TIL expansions. Holds remain on REGENXBIO’s MPS I and II trials due to a tumor incident.
FDA Approves Novo Nordisk’s First Daily Oral GLP-1 for Weight Management
Novo Nordisk's once-daily oral GLP-1 pill matches injectable weight loss results and reduces cardiovascular risk by ~20% in high-risk patients. Approved for obesity and overweight with heart disease, transforming treatment accessibility. Expected US launch in early 2026.
US Set to Exit WHO, Sparking Global Health Concerns
The United States will officially leave the World Health Organization on January 29, 2026, raising alarms for international health coordination. Critics worry about impacts on pandemic response and global disease surveillance. This follows ongoing debates on WHO funding and efficacy.
Scientists Warn Influenza D and Canine Coronavirus as Emerging Threats
Experts highlight influenza D virus and canine coronavirus as potential public health risks if surveillance lags. These zoonotic pathogens could trigger outbreaks without improved diagnostics. Similar warnings issued by UF Health researchers.
Optimism for Pancreatic Cancer Advances in 2026 Detection and Therapies
Pancreatic cancer projections: 67,530 US diagnoses, 52,740 deaths in 2026, but progress in early detection, precision medicine, and trials like TTFields under FDA review. Targets include PRMT5 inhibition for MTAP-loss tumors and novel surgical strategies.
WHO Marks World NTD Day and Reports Marburg Outbreak End in Ethiopia
WHO announces end of Marburg outbreak in Ethiopia alongside World NTD Day on January 30 calling to 'Unite. Act. Eliminate.' Ongoing updates on seasonal influenza, avian flu in USA, and COVID-19. Highlights include Pandemic Agreement and cancer initiatives.
Acrivon Reports High Response Rates in Endometrial Cancer Trial
Acrivon’s ACR-368 Phase 2 trial shows over 50% confirmed response in serous endometrial cancer patients with up to two prior therapies. This supports rapid enrollment expansion in US and EU without pretreatment biopsy. Part of 2026's late-stage cancer breakthroughs.